These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2904706)

  • 41. Stimulation of human platelet guanylate cyclase by nitroso compounds.
    Yamakado T; Nishikawa M; Hidaka H
    Thromb Res; 1982 Apr; 26(2):135-40. PubMed ID: 6126017
    [No Abstract]   [Full Text] [Related]  

  • 42. Activation of endothelial guanylate cyclase inhibits cellular reactivity.
    Heller R; Bussolino F; Ghigo D; Pescarmona GP; Calvino R; Gasco A; Till U; Bosia A
    Agents Actions Suppl; 1995; 45():177-81. PubMed ID: 7717176
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Soluble guanylate cyclase in the molecular mechanism underlying the therapeutic action of drugs].
    Piatakova NV; Severina IS
    Biomed Khim; 2012; 58(1):32-42. PubMed ID: 22642150
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mode of action of nitrates with regard to vasodilatation and tolerance.
    Kukovetz WR; Holzmann S
    Z Kardiol; 1986; 75 Suppl 3():8-11. PubMed ID: 2879392
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Benzodifuroxan as an NO-dependent activator of soluble guanylate cyclase and a novel highly effective inhibitor of platelet aggregation.
    Bussygina OG; Pyatakova NV; Khropov YV; Ovchinnikov IV; Makhova NN; Severina IS
    Biochemistry (Mosc); 2000 Apr; 65(4):457-62. PubMed ID: 10810184
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiplatelet effects of a novel antianginal agent, nicorandil.
    Jaraki O; Strauss WE; Francis S; Loscalzo J; Stamler JS
    J Cardiovasc Pharmacol; 1994 Jan; 23(1):24-30. PubMed ID: 7511731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase.
    Chlopicki S; Olszanecki R; Marcinkiewicz E; Lomnicka M; Motterlini R
    Cardiovasc Res; 2006 Jul; 71(2):393-401. PubMed ID: 16713591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular mechanisms of nitrovasodilator bioactivation.
    Noack E; Feelisch M
    Basic Res Cardiol; 1991; 86 Suppl 2():37-50. PubMed ID: 1683227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-activity relationship of organic nitrates for activation of guanylate cyclase.
    Schröder H; Noack E
    Arch Int Pharmacodyn Ther; 1987 Dec; 290(2):235-46. PubMed ID: 2895614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
    Bult H; Fret HR; Herman AG
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of calcium influx in thrombin-stimulated platelets by SIN-1, an activator of soluble guanylate cyclase.
    Simon MF; Chap H
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S106-10. PubMed ID: 2484686
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On the mechanism of NO release from sydnonimines.
    Feelisch M; Ostrowski J; Noack E
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S13-22. PubMed ID: 2484692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Functional activity of platelet guanylate cyclase and cardiac hemodynamics in patients with chronic heart failure and relevant changes after treatment with isosorbide-5-mononitrate].
    Ol'binskaia LI; Ushakova AV; Sizova ZhM
    Ter Arkh; 1999; 71(9):77-9. PubMed ID: 10553632
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure.
    Negrescu EV; Sazonova LN; Baldenkov GN; Mukharliamov NM; Mazaev AV; Tkachuk VA
    Int J Cardiol; 1990 Feb; 26(2):175-84. PubMed ID: 2105912
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Conditions of activation of guanylate cyclase from human platelets].
    Chirkov IuIu; Tyshchuk IA; Severina IS
    Biokhimiia; 1988 Sep; 53(9):1520-6. PubMed ID: 2904828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries.
    Kukovetz WR; Holzmann S
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S40-6. PubMed ID: 2484698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of oxyhaemoglobin to explore the events underlying inhibition of platelet aggregation induced by NO or NO-donors.
    Salvemini D; Radziszewski W; Korbut R; Vane J
    Br J Pharmacol; 1990 Dec; 101(4):991-5. PubMed ID: 1707709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nitrovasodilators and cGMP inhibit human platelet activation.
    Doni MG; Alexandre A; Padoin E; Bertoncello S; Deana R
    Cardioscience; 1991 Sep; 2(3):161-5. PubMed ID: 1660321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of isatin on nitric oxide-stimulated soluble guanylate cyclase from human platelets.
    Medvedev A; Bussygyna O; Pyatakova N; Glover V; Severina I
    Biochem Pharmacol; 2002 Feb; 63(4):763-6. PubMed ID: 11992646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Platelet aggregation with SIN 1: comparison with isosorbide-5-mononitrate and acetylsalicylic acid].
    Gerzer R; Karrenbrock B; Niederreiter B; Heim JM; Drummer C
    Z Kardiol; 1991; 80 Suppl 5():9-11. PubMed ID: 1776339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.